Clinical trial
A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain
NCT04372121 is registered in ClinicalTrials.gov with Kissei Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 23, 2020
- Completion date
- February 16, 2021
- Enrollment
- 30 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.